Search results for: 'formulation development outsourcing'

Small molecules, which are the leading drug class across indications, face several issues that threaten their drug delivery efficacy. They suffer from off-target effects, poor bioavailability, low solubility, systemic toxicity, and poor permeability. While the small molecule drug development pipeline remains a leading therapeutic class, it is essen...

Microbiome research is on the rise following technological advancements and significant cost reductions in microbiome analysis. Research has unlocked the potential of microbiome in medical use cases, yielding tremendous insights on its nature, interactions, and impact within a host and in an external environment. Advanced studies on the role of mic...

Biologics, particularly peptide and protein therapies, are a rapidly growing therapeutic area because they can target complex biological pathways with high efficacy. These therapies are becoming important in oncology, metabolic disease, and autoimmune conditions supported by the growing global disease burden and growth in areas such as GLP-1s and m...

By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more compl...

The global small‑molecule CDMO industry is undergoing a structural transformation driven by increasing molecular complexity, patent expiries, cost pressures, and the strategic need to secure resilient pharmaceutical supply chains. Demand is shifting beyond high‑volume commodity generics toward specialized development and manufacturing capabilities ...

The global pharmaceutical industry strives to build an inclusive partner ecosystem that integrates technology, data, and regulatory standardization-enabled innovation into clinical trial delivery. This transformation aims to reduce the burden on investigators and sites while improving the efficiency and accuracy of adverse event (AE) tracking. Driv...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides actionable insights across new developments in prebiotics, immunology, oncology, cell and gene therapies, antibody therapies, and precision medicine approaches. The TOE also encompasses technology advances across the use of AI and ML in drug discovery a...

27 Jan 2020  |  Global  |  Market Research

Growth Opportunities—Contract Manufacturing and Outsourcing Opportunities in the In-vitro Diagnostics (IVD) Industry, 2019 to 2022

Consolidation and Innovative Business Models Will Accelerate IVD Outsourcing Growth

Infographics

×

Key Issues Addressed

The increasing pressure for cost-driven development and regulatory and regional trends are inducing industry participants to adopt innovative integrated business models so as to align themselves as one-stop-shop solution providers as opposed to the traditional functional service providers, thereby, creating a mutually beneficial symbiotic relations...

The SynBio field has evolved well over the past two decades, with significant technology disruptions leading to new opportunities and remarkable growth potential. Advances in SynBio technologies have transformed drug discovery and therapeutics development, accelerating the identification of novel drug targets and high-throughput compound screening ...